-

$undefined

N/A

(N/A)

Inhibikase Therapeutics :IKT

Location: | Industry: | Sector:

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

56.45M

Cash

97.54M

Avg Qtr Burn

-4.787M

Short % of Float

5.13%

Insider Ownership

11.71%

Institutional Own.

72.13%

Qtr Updated

12/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IkT-001Pro Details Cancer, Hematologic malignancies, Gastric cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IkT-001 Details Pulmonary Arterial Hypertension (PAH)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Risvodetinib (IkT-148009) Details Neurodegenerative disease, Parkinson's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.